M. Stabl

949 total citations
23 papers, 679 citations indexed

About

M. Stabl is a scholar working on Pharmacology, Psychiatry and Mental health and Biological Psychiatry. According to data from OpenAlex, M. Stabl has authored 23 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 16 papers in Psychiatry and Mental health and 3 papers in Biological Psychiatry. Recurrent topics in M. Stabl's work include Treatment of Major Depression (18 papers), Electroconvulsive Therapy Studies (12 papers) and Bipolar Disorder and Treatment (6 papers). M. Stabl is often cited by papers focused on Treatment of Major Depression (18 papers), Electroconvulsive Therapy Studies (12 papers) and Bipolar Disorder and Treatment (6 papers). M. Stabl collaborates with scholars based in Switzerland, Austria and United Kingdom. M. Stabl's co-authors include Jules Angst, R. Amrein, W. Schmid‐Burgk, Márcio Versiani, Kathleen Bizière, G. Hebenstreit, Ulf Baumhackl, Antônio Egídio Nardi, Roman Fischbach and A. Delini‐Stula and has published in prestigious journals such as The British Journal of Psychiatry, Behaviour Research and Therapy and Psychopharmacology.

In The Last Decade

M. Stabl

23 papers receiving 619 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Stabl Switzerland 16 430 398 170 101 80 23 679
D.P. Doogan United Kingdom 11 478 1.1× 399 1.0× 177 1.0× 158 1.6× 103 1.3× 14 765
Peter H. Silverstone Canada 18 223 0.5× 348 0.9× 134 0.8× 281 2.8× 55 0.7× 30 912
Alan D. Feiger United States 12 447 1.0× 350 0.9× 233 1.4× 106 1.0× 89 1.1× 16 708
Meghan M. Grady United States 9 317 0.7× 334 0.8× 124 0.7× 137 1.4× 103 1.3× 16 808
P. J. Perry United States 12 216 0.5× 526 1.3× 97 0.6× 138 1.4× 89 1.1× 20 872
D. Montgomery United Kingdom 16 383 0.9× 366 0.9× 156 0.9× 130 1.3× 136 1.7× 33 731
Burton J. Goldstein United States 14 242 0.6× 233 0.6× 176 1.0× 198 2.0× 57 0.7× 47 755
D. Tuck Sweden 7 453 1.1× 363 0.9× 99 0.6× 262 2.6× 78 1.0× 8 827
Alessandra Signoretti Italy 7 319 0.7× 306 0.8× 155 0.9× 78 0.8× 91 1.1× 9 730
Hans‐Juergen Moeller Germany 10 240 0.6× 388 1.0× 63 0.4× 140 1.4× 59 0.7× 13 844

Countries citing papers authored by M. Stabl

Since Specialization
Citations

This map shows the geographic impact of M. Stabl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Stabl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Stabl more than expected).

Fields of papers citing papers by M. Stabl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Stabl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Stabl. The network helps show where M. Stabl may publish in the future.

Co-authorship network of co-authors of M. Stabl

This figure shows the co-authorship network connecting the top 25 collaborators of M. Stabl. A scholar is included among the top collaborators of M. Stabl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Stabl. M. Stabl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Versiani, Márcio, R. Amrein, & M. Stabl. (1997). Moclobemide and imipramine in chronic depression (dysthymia). International Clinical Psychopharmacology. 12(4). 183–194. 35 indexed citations
2.
3.
4.
Angst, Jules, R. Amrein, & M. Stabl. (1996). Moclobemide: a paradigm of research in clinical psychopharmacology. International Clinical Psychopharmacology. 11(Supplement 3). 3–7. 3 indexed citations
5.
Dingemanse, Jasper, Theodor W. Guentert, Ronald Gieschke, & M. Stabl. (1996). Modification of the Cardiovascular Effects of Ephedrine by the Reversible Monoamine Oxidase A-Inhibitor Moclobemide. Journal of Cardiovascular Pharmacology. 28(6). 856–861. 10 indexed citations
6.
Lecrubier, Y., et al.. (1995). Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. Acta Psychiatrica Scandinavica. 92(4). 260–265. 11 indexed citations
7.
Angst, Jules, et al.. (1995). Moclobemide and Tricyclic Antidepressants in Severe Depression. Journal of Clinical Psychopharmacology. 15(4 Suppl 2). 16S–23S. 46 indexed citations
8.
Stabl, M., et al.. (1995). A Double-Blind Comparison of Moclobemide and Thioridazine Versus Moclobemide and Placebo in the Treatment of Refractory, Severe Depression. Journal of Clinical Psychopharmacology. 15(4 Suppl 2). 41S–45S. 12 indexed citations
9.
Moll, Etelka, et al.. (1994). Safety and Efficacy During Long-Term Treatment with Moclobemide. Clinical Neuropharmacology. 17. S74–S87. 19 indexed citations
10.
Wardle, Jane, Peter Hayward, Anna Higgitt, et al.. (1994). Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. Behaviour Research and Therapy. 32(2). 203–215. 39 indexed citations
11.
Amrein, R., W. Hetzel, M. Stabl, & W. Schmid‐Burgk. (1993). RIMA — A new concept in the treatment of depression with moclobemide. International Clinical Psychopharmacology. 7(3). 123–132. 27 indexed citations
12.
Heinze, Gerhard, et al.. (1993). Double-Blind Comparison of Moclobemide and Tranylcypromine in Depression. Pharmacopsychiatry. 26(6). 240–245. 13 indexed citations
13.
Angst, Jules & M. Stabl. (1992). Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology. 106(S1). S109–S113. 76 indexed citations
14.
15.
Amrein, R., et al.. (1992). Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology. 106(S1). S24–S31. 37 indexed citations
16.
Hebenstreit, G., Ulf Baumhackl, B. Gallhofer, et al.. (1990). Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind Multicenter Study, Austria. PubMed. 32. 177–184. 3 indexed citations
17.
Versiani, Márcio, et al.. (1990). Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo. Acta Psychiatrica Scandinavica. 82(S360). 24–28. 42 indexed citations
18.
Baumhackl, Ulf, et al.. (1989). Efficacy and Tolerability of Moclobemide Compared with Imipramine in Depressive Disorder (DSM-III): An Austrian Double-blind, Multicentre Study∗. The British Journal of Psychiatry. 155(S6). 78–83. 80 indexed citations
19.
Stabl, M., Kathleen Bizière, W. Schmid‐Burgk, & R. Amrein. (1989). Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states.. PubMed. 28. 77–89. 32 indexed citations
20.
Amrein, R., et al.. (1988). Antidepressant drug therapy: associated risks.. PubMed. 26. 73–86. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D.P. Doogan Breakdown of academic impact, for papers by Peter H. Silverstone Breakdown of academic impact, for papers by Alan D. Feiger Breakdown of academic impact, for papers by Meghan M. Grady Breakdown of academic impact, for papers by P. J. Perry Breakdown of academic impact, for papers by D. Montgomery Breakdown of academic impact, for papers by Burton J. Goldstein Breakdown of academic impact, for papers by D. Tuck Breakdown of academic impact, for papers by Alessandra Signoretti Breakdown of academic impact, for papers by Hans‐Juergen Moeller
Rankless by CCL
2026